Webcast CME

Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice Webcast

Print this Content

Release date: January 19, 2024
Expiration date: January 19, 2026

Estimated Time of Completion: 2 hours and 45 minutes

Description

Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice Webcast provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with AA, PNH, MDS, AML, MPN and related myeloid malignancies. The overall goal of the education is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Learning Objectives

  • Describe risk factors and implications of clonal hematopoiesis and potential strategies to modify the natural history of clonal hematopoiesis.
  • Outline best available evidence in managing patients with PNH.
  • Formulate appropriate evaluation and management strategies for patients with aplastic anemia and other bone marrow failure conditions.
  • Critically review the MDS diagnostic criteria in light of recent changes in disease nomenclature and describe expanding treatment strategies for low-risk and high-risk MDS.
  • Describe the new diagnostic criteria for AML and how to make personalized treatment decisions in patients with AML.  
  • Critically appraise the indications, efficacy, and adverse events for the expanding treatment options for patients with myeloproliferative neoplasms.
  • Synthesize current research on the role of cellular therapies in AML and their future potential.

Target Audience

The webcast designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians, nurses, advanced practice nurses, physician assistants and allied health care professionals treating patients with AA, PNH, MDS, AML, MPN and myeloid malignancies.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Cleveland Clinic Center for Continuing Education and Aplastic Anemia and MDS International Foundation, Inc. Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA) 
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit. 

American Nurses Credentialing Center (ANCC) 
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 2.75 ANCC contact hours. 

American Academy of PAs (AAPA) 
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Certificate of Participation

A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

Activity Director and Faculty

Activity Director

Sudipto Mukherjee, MD, PhD, MPH
Cleveland Clinic
Cleveland, OH

Faculty

Uma M. Borate, MBBS, MS
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Marco Davila, MD, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Austin Kulasekararaj, MD, PhD, MPH
King’s College Hospital
London, England

Esther Natalie Oliva, MD
Grande Ospedale Metropolitano Bianchi Melacrino Morelli
Reggio Calabria, Italy

Kristen Marie Pettit, MD
University of Michigan
Ann Arbor, MI

Abhay Singh, MD, MPH
Cleveland Clinic
Cleveland, OH

Additional Planners/Reviewers

Deb Kangisser, PA-C

Cindy Willis, DNP

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Uma M Borate, MD

RUNX1 Foundation

Other activities from which remuneration is received or expected: Honorarium Recipient

Abbvie Pharmaceuticals

Other activities from which remuneration is received or expected: Advisory Board Membership
Research: PI

Incyte, Jazz Pharmaceuticals, Pfizer

Research: PI

Astellas Pharma US, Inc., Blueprint Genetics, Genentech, Kura, Novartis Pharmaceuticals, Servier Laboratories, Takeda

Other activities from which remuneration is received or expected: Advisory Board Membership

Marco Davila, MD, PhD

CRISPR (CRSP)

Intellectual property rights (Royalties or patent sales)

Adicet ,Atara Biotherapeutics, Caribou Biosciences, Legend Biotech, Syncopation Life Sciences, Synthekine

Consulting

Capstan

Advisor or review panel participant

Adaptive Biotechnologies, Precision Biosciences

Ownership interest (stock, stock options in a publicly owned company)

Bellicum Pharmaceuticals, Inc.

Advisor or review panel participant
Ownership interest (stock, stock options in a publicly owned company)

Kite Pharma Inc.

Teaching and Speaking

Austin Kulasekararaj, MD, PhD, MPH

Alexion, Amgen, BioCryst Pharmaceuticals, Inc, F. Hoffmann-La Roche, Novartis Pharmaceuticals, Pfizer, Inc, Regeneron, SOBI

Consulting
Advisor or review panel participant
Teaching and Speaking

Celgene Corporation, Janssen Research & Development, LLC, Samsung Bioepis

Consulting
Advisor or review panel participant

Agios Pharmaceuticals, Arrowhead, Novo Nordisk, Inc., Silence Therapeutics

Consulting

Sudipto Mukherjee, MD, PhD, MPH

Bristol-Myers Squibb Co.

Advisor or review panel participant
Other activities from which remuneration is received or expected: Honoraria

Celgene Corporation

Consulting
Advisor or review panel participant
Other activities from which remuneration is received or expected: Research Funding - non-therapeutic investigator trials. Formerly Celgene (now BMS)

Eusa Pharma

Consulting
Advisor or review panel participant
Teaching and Speaking

Novartis

Consulting
Advisor or review panel participant

Jazz Pharmaceuticals

Research: Principal Investigator for Investigator Initiated Trials (The institution gets the funding)

Abbvie Pharmaceuticals, Blueprint Medicines

Advisor or review panel participant

McGraw Hill

Other activities from which remuneration is received or expected: Honoraria - Editor of Hematology Oncology Board Review (ongoing)

Aplastic Anemia and MDS International Foundation

Other activities from which remuneration is received or expected: Honorarium - Activity Director of ASH Friday Satellite Symposium annually

Esther Natalie Olivia, MD

BMS

Advisor or review panel participant
Teaching and Speaking

Kristen Marie Pettit, MD

Abbvie Pharmaceuticals, Incyte, Sierra Oncology

Advisor or review panel participant

Abhay Singh, MD

Rigel

Advisor or review panel participant

The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:

Debra Kangisser, PA-C
Cynthia Willis, DNP

 

Acknowledgement

The Cleveland Clinic Center for Continuing Education and the Aplastic Anemia and MDS International Foundation, Inc. acknowledge educational grants for partial support of this Internet Enduring activity from:

Apellis Pharmaceuticals, Inc.
Bristol Myers Squibb Company
Genentech, Inc.
Geron Corporation
Incyte Corporation
Novartis Pharmaceuticals Corporation
Taiho Oncology, Inc.

 

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia and MDS International Foundation, Inc.